Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Expenses
Research and development	$ 15,173	$ 11,815
General and administrative	7,509	9,757
Merger costs		500
In-process research and development		16,094
Operating expenses	(22,682)	(38,166)
Other income (loss)
Foreign exchange	7	(12)
Amortization of deferred loan costs		(94)
Interest - net	14	(26)
Other loss (income)	21	(132)
Net loss for the year	(22,661)	(38,298)
Computation of basic loss per share
Net loss for the year	(22,661)	(38,298)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance		(3,181)
Series A Preferred cash dividend	(8)	(8)
Net loss for the year attributable to common stockholders	$ (25,131)	$ (41,504)
Basic and fully diluted loss per share	$ (0.52)	$ (1.60)
Basic and fully diluted weighted average number of shares	48,702,000	25,886,000
Preferred Stock Series B
Computation of basic loss per share
Preferred stock dividend		$ (17)
Preferred Stock Series C
Computation of basic loss per share
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance		$ (3,181)
Preferred stock dividend	$ (2,462)